Genetic damage from medical device materials represents one of the most serious safety concerns - mutagenic substances causing DNA damage can lead to cancer development, making genotoxicity assessment mandatory before any device contacts patients for extended periods. The bacterial reverse mutation test, commonly known as the Ames test, serves as the primary screening method for mutagenic potential following ISO 10993-3 and OECD TG471 guidelines, detecting substances that cause point mutations in bacterial DNA that could indicate cancer risk in humans. This fundamental test exposes multiple Salmonella typhimurium strains and Escherichia coli to device extracts, measuring mutation frequency through reversion to histidine independence, with metabolic activation systems simulating human liver metabolism that converts some substances to mutagenic metabolites. Regulatory bodies worldwide require Ames testing for all medical devices with patient contact exceeding 24 hours per ISO 10993-1, implantable devices regardless of duration, and any device where chemical characterization reveals potentially mutagenic substances requiring biological confirmation. The test's high sensitivity detects mutagenic activity at concentrations below those causing cytotoxicity, providing early warning about materials requiring reformulation or additional safety assessment before expensive animal studies or clinical trials commence. For medical device manufacturers, passing Ames test results enable progression through biological evaluation pathways, while positive results trigger immediate investigation of material composition, extraction conditions, or processing residues potentially introducing mutagenic contamination. The comprehensive test protocol employs both polar and non-polar extracts ensuring detection of mutagenic substances regardless of solubility, uses multiple bacterial strains detecting different mutation types including base-pair substitutions and frameshift mutations, and includes metabolic activation revealing substances requiring bioactivation to express mutagenic potential. Critical applications include testing novel biomaterials where mutagenic potential remains unknown, validating that sterilization processes don't generate mutagenic degradation products through material reactions, and demonstrating that manufacturing changes don't introduce mutagenic contamination requiring revalidation.